EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI

Laiz Laura de Godoy, Kheng Choon Lim, Archith Rajan, Gaurav Verma, Mauro Hanaoka, Donald M O'Rourke, John Y K Lee, Arati Desai, Sanjeev Chawla iD, Suyash Mohan iD

Cancers · 07.09.2023 · 15 (18) · 4453

DOI: 10.3390/cancers15184453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 07.09.2023. Verfasst von Laiz Laura de Godoy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose: The isocitrate dehydrogenase (IDH) mutation has become one of the most important prognostic biomarkers in glioma management, indicating better treatment response and prognosis. IDH mutations confer neomorphic activity leading to the conversion of alpha-ketoglutarate (α-KG) to 2-hydroxyglutarate (2HG). The purpose of this study was to investigate the clinical potential of proton MR spectroscopy (1H-MRS) in identifying IDH-mutant gliomas by detecting characteristic resonances of 2HG and its complex interplay with other clinically relevant metabolites. Materials and Methods: Thirty-two patients with suspected infiltrative glioma underwent a single-voxel (SVS, n = 17) and/or single-slice-multivoxel (1H-MRSI, n = 15) proton MR spectroscopy (1H-MRS) sequence with an optimized echo-time (97 ms) on 3T-MRI. Spectroscopy data were analyzed using the linear combination (LC) model. Cramér–Rao lower bound (CRLB) values of

Schlagwörter

Stichwörter der Autor:innen

2-hydroxyglutarategliomaisocitrate dehydrogenaseproton MR spectroscopy

Autor:innen und Institutionen

  • Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Neuroradiology, Singapore General Hospital, Singapore 169609, Singapore.
  • Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Glioblastoma Translational Center of Excellence, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19014, USA.

ORCID-Profile: Sanjeev Chawla, Suyash Mohan

Zitieren

APA

de Godoy, L. L., Lim, K. C., Rajan, A., Verma, G., Hanaoka, M., O'Rourke, D. M., Lee, J. Y. K., Desai, A., Chawla, S., & Mohan, S. (2023). Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI. Cancers, 15(18), 4453. https://doi.org/10.3390/cancers15184453

Vancouver

de Godoy LL, Lim KC, Rajan A, Verma G, Hanaoka M, O'Rourke DM, et al. Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI. Cancers. 2023;15(18):4453. doi:10.3390/cancers15184453

BibTeX
@article{deGodoy2023,
  author = {de Godoy, Laiz Laura and Lim, Kheng Choon and Rajan, Archith and Verma, Gaurav and Hanaoka, Mauro and O'Rourke, Donald M and Lee, John Y K and Desai, Arati and Chawla, Sanjeev and Mohan, Suyash},
  title = {Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {18},
  pages = {4453},
  doi = {10.3390/cancers15184453}
}
Kostenlos starten →